Format

Send to

Choose Destination
Exp Biol Med (Maywood). 2019 Jan;244(1):42-51. doi: 10.1177/1535370218824547. Epub 2019 Jan 21.

IL-12 and IL-23/Th17 axis in systemic lupus erythematosus.

Author information

1
1 Department of Medicine-DIMED, Division of Rheumatology, University of Padova, 35128 Padova, Italy.
2
2 Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, 3000-075 Coimbra, Portugal.
3
3 Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, 3004-504 Coimbra, Portugal.
4
4 Faculty of Health Sciences, University of Beira Interior, 6201-001 Covilhã, Portugal.

Abstract

Our article is focused on emerging pathogenetic pathways in systemic lupus erythematosus (SLE). Notably, IL-12 and IL-23 have been described as emerging cytokines in SLE pathogenesis. We know that IL-23 stimulates Th17 cells to produce IL-17. We try to point out the importance of IL-23/Th17 axis in SLE and to focus on the interaction between this axis and IL-12. Ustekinumab, a fully human IgG1κ monoclonal antibody directed towards the p40 shared subunit of IL-12 and IL-23, has been recently investigated in SLE, suggesting a potential novel therapeutic strategy in SLE. To our knowledge, there are no reviews which simultaneously focus on IL-12 an IL-23/Th17 axis in SLE. Thus, we believe our work will be of interest to the readers.

KEYWORDS:

IL-12; IL-23/Th17 axis; SLE; Th1 response; immune response; ustekinumab

PMID:
30664357
PMCID:
PMC6362534
[Available on 2020-01-01]
DOI:
10.1177/1535370218824547

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center